toremifene (Fareston)

Indications

• metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor unknown tumors

Pharmacokinetics

• metabolized in the liver by cyt P450 3A4

elimination via liver

Drug interactions

• any drug that inhibits cyt P450 3A4 may increase levels of toremifene
• any drug that induces cyt P450 3A4 may diminish levels of toremifene

Mechanism of action

• selective estrogen receptor modulator (SERM)

More general terms

• antineoplastic endocrine agent

Additional terms

• breast cancer
• cytochrome P450 3A4 (cytochrome P450 C3, nifedipine oxidase, P450-PCN1, NF-25, CYP3A4)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3005573
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3005572
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5516
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=56008